Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Other Non-Current Assets (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Other Non-Current Assets for 6 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets fell 36.95% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 36.95% decrease, with the full-year FY2025 number at $1.3 million, down 36.95% from a year prior.
  • Other Non-Current Assets was $1.3 million for Q4 2025 at Relay Therapeutics, down from $2.3 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $2.7 million in Q2 2023 to a low of $878000.0 in Q1 2021.
  • A 5-year average of $2.4 million and a median of $2.6 million in 2021 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: surged 11618.18% in 2021, then tumbled 36.95% in 2025.
  • Relay Therapeutics' Other Non-Current Assets stood at $2.6 million in 2021, then changed by 0.0% to $2.6 million in 2022, then rose by 5.0% to $2.7 million in 2023, then decreased by 21.72% to $2.1 million in 2024, then crashed by 36.95% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Other Non-Current Assets are $1.3 million (Q4 2025), $2.3 million (Q3 2025), and $2.3 million (Q2 2025).